Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 10/20 | 0.55 |
| ▸ | FLT3 | P36888 | 2/20 | 0.55 |
| ▸ | MET | P08581 | 3/20 | 0.53 |
| ▸ | EGFR | P00533 | 8/20 | 0.51 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.49 |
| ▸ | ROS1 | P08922 | 2/20 | 0.48 |
| ▸ | AXL | P30530 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL886705 | 0.82 | ALK (0.59) | ALKFLT3METEGFRROS1 | |
| SCHEMBL886036 | 0.80 | ALK (0.59) | ALKFLT3METEGFRROS1 | |
| Hydrochloric Acid SCHEMBL2060488 | 0.80 | ALK (0.58) | ALKFLT3METEGFRROS1 | |
| SCHEMBL885843 | 0.79 | ALK (0.58) | ALKFLT3METEGFRGLO1 | |
| SCHEMBL29190607 | 0.76 | ALK (0.63) | ALKFLT3METEGFRGLO1 | |
| SCHEMBL29190526 | 0.75 | ALK (0.57) | ALKFLT3METEGFRGLO1 | |
| Hydrochloric Acid SCHEMBL29051911 | 0.74 | PTK2 (0.51) | ALKFLT3MET | |
| SCHEMBL1039383 | 0.74 | MAPK9 (0.66) | ALKFLT3METEGFRGLO1 | |
| SCHEMBL29190590 | 0.74 | ALK (0.70) | ALKFLT3METEGFRGLO1 | |
| SCHEMBL1036294 | 0.73 | ALK (0.68) | ALKFLT3METEGFRGLO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221555-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND c-MET INHIBITORS | CEPHALON, INC. (US) | 2009-09-03 | — | — | US | claimed |
| US-8148391-B2 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors | CEPHALON, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20090221555-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND c-MET INHIBITORS | CEPHALON, INC. (US) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221555-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND c-MET INHIBITORS | ALK, MET, RET | ALK 1/4885FLT3 14/4885MET 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.